125 related articles for article (PubMed ID: 19356027)
1. Involvement of cytochromes P450 2D6, 2B6 and 2C19 in the metabolism of (-)-deprenyl and N-methyl,N-propargylphenylethylamine.
Rittenbach KA; Baker GB
Drug Metab Lett; 2007 Apr; 1(2):97-100. PubMed ID: 19356027
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of N-methyl, N-propargylphenylethylamine: studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes.
Rittenbach KA; Holt A; Ling L; Shan J; Baker GB
Cell Mol Neurobiol; 2007 Mar; 27(2):179-90. PubMed ID: 17160483
[TBL] [Abstract][Full Text] [Related]
3. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.
Chang Y; Fang WB; Lin SN; Moody DE
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):55-62. PubMed ID: 20825389
[TBL] [Abstract][Full Text] [Related]
4. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.
Benetton SA; Fang C; Yang YO; Alok R; Year M; Lin CC; Yeh LT
Drug Metab Pharmacokinet; 2007 Apr; 22(2):78-87. PubMed ID: 17495414
[TBL] [Abstract][Full Text] [Related]
5. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes.
Hidestrand M; Oscarson M; Salonen JS; Nyman L; Pelkonen O; Turpeinen M; Ingelman-Sundberg M
Drug Metab Dispos; 2001 Nov; 29(11):1480-4. PubMed ID: 11602525
[TBL] [Abstract][Full Text] [Related]
6. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily.
Ono S; Hatanaka T; Miyazawa S; Tsutsui M; Aoyama T; Gonzalez FJ; Satoh T
Xenobiotica; 1996 Nov; 26(11):1155-66. PubMed ID: 8948091
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
8. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes.
Postlind H; DanielsonA ; Lindgren A; Andersson SH
Drug Metab Dispos; 1998 Apr; 26(4):289-93. PubMed ID: 9531513
[TBL] [Abstract][Full Text] [Related]
9. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers.
Meyer MR; Peters FT; Maurer HH
Biochem Pharmacol; 2009 Jun; 77(11):1725-34. PubMed ID: 19428327
[TBL] [Abstract][Full Text] [Related]
11. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
12. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.
Yamazaki H; Shimada T
Xenobiotica; 1999 Mar; 29(3):231-41. PubMed ID: 10219964
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of tauromustine in liver and lung microsomes from various species.
Tuvesson H; Gunnarsson PO; Seidegård J
Xenobiotica; 1999 Aug; 29(8):783-92. PubMed ID: 10553719
[TBL] [Abstract][Full Text] [Related]
15. Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism.
Lewis DF; Lake BG; Dickins M
Drug Metabol Drug Interact; 2004; 20(3):111-42. PubMed ID: 15508429
[TBL] [Abstract][Full Text] [Related]
16. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans.
Yaïch M; Popon M; Médard Y; Aigrain EJ
Pharmacogenetics; 1998 Oct; 8(5):449-51. PubMed ID: 9825837
[TBL] [Abstract][Full Text] [Related]
17. Measurement of in vitro cytochrome P450 2B6 activity.
Walsky RL; Obach RS
Curr Protoc Toxicol; 2009; Chapter 4():Unit4.27. PubMed ID: 23045012
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450-dependent toxicity of dapsone in human erythrocytes.
Ganesan S; Sahu R; Walker LA; Tekwani BL
J Appl Toxicol; 2010 Apr; 30(3):271-5. PubMed ID: 19998329
[TBL] [Abstract][Full Text] [Related]
20. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]